TRENDY

Telmisartan versus Ramipril in renal ENdothelial DYsfunction.

TRENDY examined the endothelial function of the renal vasculature in type 2 diabetes

Why conduct this study?

Endothelial dysfunction is one of the earliest signs of vascular damage in a range of different diseases, including diabetes, hypertension, hypercholesterolaemia and coronary heart disease.¹ In the kidney, endothelial dysfunction can result in intraglomerular hypertension and inflammation, and consequently albuminuria.

Angiotensin II can worsen endothelial dysfunction by increasing blood pressure and oxidative stress.² As a result of their actions on the renin-angiotensin system, the angiotensin II receptor blockers (ARBs) losartan and irbesartan have been shown to exert a protective effect, even in the early stages of renal disease.³ Other ARBs and ACE inhibitors may also exert such a protective effect.

The aim of the TRENDY study was to compare the mid-term effects of MICARDIS^® and ramipril on renal plasma flow after stimulation with an inhibitor of endothelium-dependent vasorelaxation (induced by nitrous oxide) in patients with type 2 diabetes and mild-to-moderate hypertension.⁴

References